ClinicalTrials.gg
RecruitingNCT02440763EUROSCA-NHSUpdated Jun 29, 2017

The EUROSCA Natural History Study

An observational study in Spinocerebellar Ataxia, sponsored by Ataxia Study Group. Recruiting at 16 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-29.

Sponsored by Ataxia Study Group · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Study summary

The key goals of EUROSCA-NHS is to determine and compare the rate of disease progression in SCA1, SCA2, SCA3 and SCA6 including determination of the order and occurrence of non-ataxia symptoms, assessment of activities of daily living (ADL) and quality of life (QoL), and identification of predictors of disease progression and survival.

Read the detailed description

The key goal of EUROSCA-NHS is to determine and compare the rate of disease progression in SCA1, SCA2, SCA3 and SCA6. To this end, a newly developed and validated ataxia scale (Scale for the Assessment and Rating of Ataxia, SARA) will be used. EUROSCA-NHS has a number of secondary aims including determination of the order and occurrence of non-ataxia symptoms, assessment of activities of daily living (ADL) and quality of life (QoL), and identification of predictors of disease progression and survival. Substudies will deal with the development of brain atrophy, as assessed by magnetic resonance imaging (MRI), progression of peripheral neuropathy, as assessed by nerve conduction studies, and specific clinical aspects of SCA.

02

Conditions studied

  • Spinocerebellar Ataxia

Keywords

  • Natural History
03

In context

Spinocerebellar Ataxias

95 studies on the registry are indexed under Spinocerebellar Ataxias; 25 are open to participants now.

This study's planned enrollment of 400 is above the median of 128 across 25 observational studies indexed under Spinocerebellar Ataxias.

Browse Spinocerebellar Ataxias studies →

Lead sponsor

Ataxia Study Group is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with spinocerebellar ataxia type 1,2,3 and 6.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Progressive, otherwise unexplained ataxia
  • Positive genetic testing for SCA1, SCA2, SCA3, and SCA6
  • Written by the patient or his legal agent

Exclusion criteria

Exclusion criteria:

None.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Spinocerebellar ataxia type 1,2,3 and 6

    Spinocerebellar ataxias (SCA) are autosomal dominantly inherited progressive ataxia disorders. An epidemiological study performed in the Netherlands found a prevalence of 3.0 : 100,000 (van de Warrenburg et al. 2002). The SCA´s are genetically and clinically heterogeneous disorders with SCA1, SCA2, SCA3 and SCA6 being the most frequent genotypes worldwide. While SCA1, SCA2 and SCA3 have a complex phenotype, SCA6 patients usually present with pure cerebellar ataxia (Schols et al. 2004). Although precise knowledge of the rate of disease progression is a prerequisite for the biometrical design of future therapeutical trials, prospective studies of the natural history of SCA´s have not been performed. Similarly, the occurrence and evolution of accompanying non-ataxia symptoms have not been studied prospectively.

06

What researchers measure

Primary outcomes

  1. Scale for the assessment and rating of ataxia (SARA)

    Progression of ataxia is measured using a newly developed and validated ataxia scale, SARA. SARA was evaluated in two large validation trials performed by the EUROSCA clinical group and was found to be easy to use, reliable, and valid.

    Time frame: Patients are first seen at a baseline visit, followed by annual visits for 3 years scheduled ± 3 months around the specified time point. After the initial 3 year observation period, visits are done at irregular intervals each time they went to hospital.

Secondary outcomes

  1. Disease stages

    Disease stages are measured using the 5 point scale ranging from 0 to 4 proposed by Klockgether et al., 1998.

    Time frame: Patients are first seen at a baseline visit, followed by annual visits for 3 years scheduled ± 3 months around the specified time point. After the initial 3 year observation period, visits are done at irregular intervals each time they went to hospital.

  2. Inventory of non-ataxia signs (INAS)

    The occurrence of accompanying non-ataxia symptoms is recorded using INAS. In the SARA validation trials, INAS was applied to a large number of SCA patients. Statistical evaluation showed good reliability.

    Time frame: Patients are first seen at a baseline visit, followed by annual visits for 3 years scheduled ± 3 months around the specified time point. After the initial 3 year observation period, visits are done at irregular intervals each time they went to hospital.

  3. UHDRS part IV

    Functional disability in ADL is assessed using the Functional assessment part of the Unified Huntington's Disease Rating Scale (UHDRS) (Huntington Study Group, 1996). This 25-item assessment has been used in SCA patients throughout the SARA validation study with good practicality.

    Time frame: Patients are first seen at a baseline visit, followed by annual visits for 3 years scheduled ± 3 months around the specified time point. After the initial 3 year observation period, visits are done at irregular intervals each time they went to hospital.

  4. EQ-5D

    Health related Quality of life is assessed using EQ-5D, a generic instrument that has been developed and validated by the EuroQuol Group (1990) and is available in validated translations for use as a questionnaire.

    Time frame: Patients are first seen at a baseline visit, followed by annual visits for 3 years scheduled ± 3 months around the specified time point. After the initial 3 year observation period, visits are done at irregular intervals each time they went to hospital.

  5. PHQ-9

    Assessment of depressive symptoms is done using a validated 9-item short form of the Patient Health Questionnaire (PHQ), a questionnaire that has been developed to screen for psychiatric co-morbidity in unselected populations (Spitzer et al. 1999).

    Time frame: Patients are first seen at a baseline visit, followed by annual visits for 3 years scheduled ± 3 months around the specified time point. After the initial 3 year observation period, visits are done at irregular intervals each time they went to hospital.

07

Study locations

1 of 16 sites recruiting
  • Department of Neurology, Medical University, Innsbruck
    Innsbruck, Austria
    Active, not recruiting

    Not enrolling at this site.

  • Université Libre de Bruxelles (ULB), Neurology Service - ULB Hôpital Erasme, ULB Laboratory of Experimental Neurology
    Brussels, Belgium
    Active, not recruiting

    Not enrolling at this site.

  • Hôpital de la Pitié-Salpêtrière, Département de Génétique
    Paris, France
    Active, not recruiting

    Not enrolling at this site.

  • Department of Neurology, St. Josef Hospital, University Hospital of Bochum
    Bochum, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Department of Neurology, University of Bonn
    Bonn, 53105, Germany
    Recruiting
  • Department of Neurology, University Clinic Essen, University of Duisburg-Essen
    Essen, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Department of Neurology, University of Frankfurt
    Frankfurt, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tübingen
    Tübingen, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Department of Medical Genetics, University of Pecs
    Pecs, Hungary
    Active, not recruiting

    Not enrolling at this site.

  • Department of Neurology, Zala County Hospital
    Zalaegerszeg, Hungary
    Active, not recruiting

    Not enrolling at this site.

  • Fondazione-IRCCS Istituto Neurologico Carlo Besta
    Milan, Italy
    Active, not recruiting

    Not enrolling at this site.

  • Department of Neuroscience, Federico II University Naples
    Naples, Italy
    Active, not recruiting

    Not enrolling at this site.

  • Radboud University Medical Center, Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour
    Nijmegen, Netherlands
    Active, not recruiting

    Not enrolling at this site.

  • Institute of Psychiatry and Neurology
    Warsaw, Poland
    Active, not recruiting

    Not enrolling at this site.

  • University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria
    Santander, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Institute of Neurology
    London, United Kingdom
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Publications

  • Diallo A, Jacobi H, Cook A, Labrum R, Durr A, Brice A, Charles P, Marelli C, Mariotti C, Nanetti L, Panzeri M, Rakowicz M, Sobanska A, Sulek A, Schmitz-Hubsch T, Schols L, Hengel H, Melegh B, Filla A, Antenora A, Infante J, Berciano J, van de Warrenburg BP, Timmann D, Boesch S, Pandolfo M, Schulz JB, Bauer P, Giunti P, Kang JS, Klockgether T, Tezenas du Montcel S. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurol. 2018 Apr;17(4):327-334. doi: 10.1016/S1474-4422(18)30042-5. Epub 2018 Mar 13. PubMed 29553382 ↗
  • Jacobi H, du Montcel ST, Bauer P, Giunti P, Cook A, Labrum R, Parkinson MH, Durr A, Brice A, Charles P, Marelli C, Mariotti C, Nanetti L, Panzeri M, Rakowicz M, Sulek A, Sobanska A, Schmitz-Hubsch T, Schols L, Hengel H, Baliko L, Melegh B, Filla A, Antenora A, Infante J, Berciano J, van de Warrenburg BP, Timmann D, Szymanski S, Boesch S, Kang JS, Pandolfo M, Schulz JB, Molho S, Diallo A, Klockgether T. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 2015 Nov;14(11):1101-8. doi: 10.1016/S1474-4422(15)00202-1. Epub 2015 Sep 13. PubMed 26377379 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Jul 2050 and a completion of Jul 2050. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2015
First posted
May 12, 2015
Start
Jul 2005
Primary completionEst.
Jul 2050
CompletionEst.
Jul 2050
Last update
Jun 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02440763
Lead sponsor
Ataxia Study Group
Responsible party
Sponsor
First posted
May 12, 2015
Start date
Jul 2005
Primary completion
Jul 2050 (estimated)
Completion
Jul 2050 (estimated)
Last update
Jun 29, 2017

Study contacts

Thomas Klockgether, Prof. Dr.
Contact
thomas.klockgether@ukb.uni-bonn.de
+4922828715736
Heike Jacobi, Dr.
Contact
heike.jacobi@ukb.uni-bonn.de

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion